Preveceutical Medical Inc · CSE:PREV
Preveceutical Medical — Investor Presentation (July 2024)
21 slides from Preveceutical Medical's investor presentation, July 2024
Slide 1: Corporate Presentation: Non-Addictive Endogenous, Opioid-Based Analgesics
CORPORATE PRESENTATION -NON-ADDICTIVE ENDOGENOUS, OPIOID- BASED ANALGESICS July 2024 CSE: PREV OTCQB: PRVCF FSE: 18H
Slide 2: Disclaimer
DISCLAIMER This presentation and its appendices (together the “Presentation”) have been prepared and delivered by PreveCeutical® Medical Inc. (“PreveCeutical” or the “Company”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H). The Presentation and its contents are strictly confidential and may not be reproduced
Slide 3: Corporate Overview
CORPORATE OVERVIEW Preventive health sciences company with corporate offices in Vancouver, Canada, and wholly owned subsidiary in Brisbane, Australia. Leveraging innovative science & technology to enhance natural products as novel targeted therapeutics in a diverse portfolio of R&D programs addressi
Slide 4: Corporate Overview: Opioid Crisis Facts and Figures
CORPORATE OVERVIEW OPIOID CRISIS – THE FACTS Since 1999, >600,000 people in the USA & Canada have died from an opioid overdose1 In addition, millions more became addicted or were seriously/irreversibly harmed Mortality rates in each country exceeds that of the worst of the HIV/AIDS epidemic. OPIOID
Slide 5: Non-Addictive Analgesic Peptides for Pain Management
NON-ADDICTIVE ANALGESIC PEPTIDES FOR PAIN MANAGEMENT SELECTIVELY TARGETING THE KAPPA-OPIOID RECEPTOR Clinically available opioid analgesics primarily target the Mu-opioid (MOR) receptor while also hitting targets in the A panel of peptides was designed and evaluated in a central nervous system (CNS)
Slide 6: Peptides for Pain Management: Four Completed Stages
NON-ADDICTIVE ANALGESIC PEPTIDES FOR PAIN MANAGEMENT SELECTIVELY TARGETING THE KAPPA-OPIOID RECEPTOR The following four stages spanning drug discovery-thru-preclinical proof-of-concept studies have been successfully completed: STAGE STAGE STAGE STAGE 01 02 03 04 In silico design of Dynorphin Iterati
Slide 7: Stage 1: In Silico Design of Dynorphin-Based Peptides
NON-ADDICTIVE ANALGESIC PEPTIDES FOR PAIN MANAGEMENT SELECTIVELY TARGETING THE KAPPA-OPIOID RECEPTOR STAGE 1 COMPLETED STAGE 1: In silico design of Dynorphin (DYN)-based peptide fragments, and opioid receptor docking/affinity screening studies. › Using DYN1-7 as our model fragment, a library of >100
Slide 8: Stage 2: Peptide Libraries and In Vitro Screening
NON-ADDICTIVE ANALGESIC PEPTIDES FOR PAIN MANAGEMENT SELECTIVELY TARGETING THE KAPPA-OPIOID RECEPTOR STAGE 2 COMPLETED STAGE 2: Iterative design and synthesis of DYN fragment peptide libraries with in vitro screening of kappa-opioid receptor selectivity, and metabolic stability. › Top Panel: In vitr
Slide 9: Stage 3: Metabolically Stabilized Peptide Libraries
NON-ADDICTIVE ANALGESIC PEPTIDES FOR PAIN MANAGEMENT SELECTIVELY TARGETING THE KAPPA-OPIOID RECEPTOR STAGE 3 COMPLETED STAGE 3: Engineering of metabolically-stabilized DYN peptide libraries (linear and cyclised), retaining exquisite KOR-selectivity while displaying reduced desensitization, and biase
Slide 10: Stage 4: Rodent Model of Inflammatory Pain
NON-ADDICTIVE ANALGESIC PEPTIDES FOR PAIN MANAGEMENT SELECTIVELY TARGETING THE KAPPA-OPIOID RECEPTOR STAGE 3 COMPLETED STAGE 4: Select peptides evaluated in a Freud’s Complete Adjuvant (FCA) rodent model of inflammatory pain, demonstrating analgesia comparable to the clinically used opiates. › In vi
Slide 11: Completed Studies and Proposed Studies
NON-ADDICTIVE ANALGESIC PEPTIDES FOR PAIN MANAGEMENT SELECTIVELY TARGETING THE KAPPA-OPIOID RECEPTOR COMPLETED STUDIES PROPOSED STUDIES WITH LINEAR & CYCLISED PEPTIDES › STAGE 1: In silico design of Dynorphin (DYN)-based peptide fragments and opioid receptor docking/affinity screening studies. › Tol
Slide 12: Non-Addictive Analgesic Project: Patent Family
NON-ADDICTIVE ANALGESIC PROJECT PATENT FAMILY PATENT NAME COUNTRY FILLING DATE PUBLICATION DATE INTERNATIONAL 26.07.2018 31.01.2019 AUSTRALIA 15.12.2022 02.02.2023 DISULFIDE BOND CONTAINING EUROPE 26.07.2018 03.06.2020 COMPOUNDS AND USES THEREOF CANADA 26.07.2018 31.01.2019 USA 11.05.2023 11.05.2023
Slide 13: PreveCeutical Team
PREVECEUTICAL TEAM Stephen Van Deventer Mak Jawadekar PhD - Chairman and Chief Executive Officer – President, Chief Science Officer and Director Mr. Van Deventer is an experienced businessman Dr. Jawadekar completed his Ph.D. in Pharmaceutics at and corporate director. Specializing in international
Slide 14: PreveCeutical Team
PREVECEUTICAL TEAM Linnéa Olofsson PhD Kathy Rokita CPA – Director – Director Dr. Olofsson is an accomplished biophysicist with 12 years of Ms. Rokita is a finance, operations, and strategey-focused laboratory research experience in academia, and 3 years executive having extensive experience with la
Slide 15: PreveCeutical Team
PREVECEUTICAL TEAM C. Evan Ballantyne Harry Parekh PhD, BSc Hons I – Director - Chief Research Officer Mr. Ballantyne has extensive executive leadership experience Based at the University of Queensland’s (UQ) Pharmacy and has spent the last 20 years as a public and private Australia Centre of Excell
Slide 16: PreveCeutical Team
PREVECEUTICAL TEAM Andrea Ortega – Executive Assistant & Office Manager Ms. Ortega is a professional currently studying commerce while gaining valuable experience in the hospitality and marketing industries over the past two years. Ms. Ortega excels at streamlining operations and optimizing marketin
Slide 17: PreveCeutical Australia Team
PREVECEUTICAL AUSTRALIA TEAM PreveCeutical® has established a wholly- owned subsidiary in Brisbane, Queensland, Australia, to bolster their research and development interests. The Australian team, which will be led by Stephen Van Deventer, the Chief Executive Officer, will work closely with Dr. Harr
Slide 18: Research Collaborators
RESEARCH COLLABORATORS Dr. Rakesh Veedu is leading the Precision Nucleic Professor Grant Ramm is currently the head of the Acids Theranostics Group, as a McCusker Research Hepatic Fibrosis Laboratory and Coordinator of the Fellow with the Perron Institute for Neurological and Cell and Molecular Biol
Slide 19: Research Collaborators
RESEARCH COLLABORATORS Dr. Ajit Shetty Aditya Bahl Dr. Shetty has extensive pharmaceutical experience Mr. Bahl brings over 20 years of experience in leading commercial and supply chain operations pharmaceutical marketing and clinical as well as significant educational background development and is k
Slide 20: Partners
PARTNERS Li} THE UNIVERSITY Vv D UMOULIN 0! OF QUEENSLAND MURDO: [B) | BLACK WF Nusteatia UNIVERSITY “fi ZB a QIMR Berghofer or fhe i” SK Smythe eo Medical Research Institute IP Amplified RAS CPA PREVECEUTICAL’
Slide 21: Please Contact
Stephen Van Deventer info@preveceutical.com PLEASE Investor Relations CONTACT ir@preveceutical.com 1 (604) 306-9669
PreveCeutical Medical — Investor Presentation (July 2024) on 6ix